Colon NRG-GI008

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Description
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology

Interested in this trial? Email [email protected].

Back To Clinical Trials NCI Database Entry